Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) traded up 6.6% during mid-day trading on Wednesday . The stock traded as high as $3.68 and last traded at $3.53, with a volume of 628,781 shares. The stock had previously closed at $3.31.

Separately, Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Tuesday, April 12th.

The stock has a 50 day moving average of $3.76 and a 200-day moving average of $4.66. The company’s market capitalization is $121.81 million.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. The company earned $1.05 million during the quarter, compared to the consensus estimate of $1.38 million. The firm’s revenue for the quarter was down 38.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.12) earnings per share. Analysts expect that Second Sight Medical Products Inc. will post ($0.65) earnings per share for the current year.

In related news, Chairman Robert J. Greenberg sold 8,223 shares of the firm’s stock in a transaction on Monday, April 18th. The stock was sold at an average price of $5.27, for a total transaction of $43,335.21. Following the sale, the chairman now owns 181,134 shares of the company’s stock, valued at approximately $954,576.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Robert J. Greenberg sold 8,571 shares of the firm’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total value of $35,141.10. Following the sale, the chairman now directly owns 172,911 shares in the company, valued at approximately $708,935.10. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Zeke Capital Advisors LLC acquired a new stake in Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products comprises about 2.5% of Zeke Capital Advisors LLC’s investment portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned 1.38% of Second Sight Medical Products at the end of the most recent quarter.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.